MAP3K11 and glioblastoma: Subsequently, the low PI3Kβ/MLK3 expressing (U-87 MG) and high PI3Kβ/MLK3 expressing (U-118 MG) GBM cells were treated with these two inhibitors in fixed ratios (AZD6482:URMC-099 = 6:1 and 10:1, respectively) to evaluate their combination effect on GBM cell proliferation.